Current share price for EPI : $0.335 0.015 (4.69%)+
Epiminder Limited (EPI), an ASX-listed company, is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy. Headquartered in Melbourne, Australia, the Company also has a presence in Sydney, Australia and in the US.
| ASX Code | EPI |
| Website | http://epiminder.com |
| Industry/Sector | Health Care Equipment |
| Market Cap ($M) | 58 |
| EPI Share Price | $0.335 |
| Day High | $0.335 |
| Day Low | $0.335 |
| Last Close | $0.320 |
| EPI Share Price Movement | $0.02 ( 4.69% ) |
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Interim | 1¢ | 0% | 22 Nov 1996 | 6 Dec 1996 | - | - | - |
See all dividends from Epiminder Limited (EPI) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$31.19 | -$17.80 | 39.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$22.39 | -$12.80 | 4.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$21.34 | -$12.20 | 0.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| Cochlear Limited (COH) | $7,919M | 0.0171 | -0.1883 | 0.0862 | 20.2329 | 24.9264 | 22.9492 | 3.55% | 2.86% | 3.06% |
| Epiminder Limited (EPI) | $55M | 0.3928 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Fisher & Paykel Healthcare Corporation Limited (FPH) | $18,787M | 0.1388 | 0.1355 | 0.1884 | 48.3744 | 42.6022 | 35.8472 | 1.36% | 1.45% | 1.64% |
| ResMed Inc. (RMD) | $16,861M | 0.3087 | 9.7634 | 0.0805 | 203.0261 | 18.8626 | 17.4571 | 1.13% | 1.19% | 1.25% |
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 0.52 | 0.00 |
| Market | 0.29 | 13.30 | 1.15 | 0.69 |
| Sector | 0.68 | 21.40 | 1.62 | 2.43 |
| Name | Position | Start Date |
|---|---|---|
| Dr Rohan Hoare | Chief Executive Officer, Managing Director | 7 Dec 2022 |
| Mr Philip Binns | Non-Executive Chairman, Non-Executive Director | 27 Jun 2018 |
| Mr Jeffrey Sells | Non-Executive Director | 4 May 2025 |
| Mr Donal Paul O'Dwyer | Non-Executive Director | 30 Apr 2025 |
| Mr Robert John Klupacs | Non-Executive Director | 25 Sep 2017 |
| Ms Patricia ORourke | Non-Executive Director | 1 Jan 0001 |
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 2 Jun 2026 | BINNS, Philip | Buy | Indirect Shares | 11,235 | $0.440 | $4,943.400 |
| 15 May 2026 | SELLS, Jeffrey | Buy | Indirect Shares | 45,475 | $0.455 | $20,691.130 |
| 15 May 2026 | KLUPACS, Robert | Buy | Direct Shares | 10,000 | $0.469 | $4,690.540 |
See all changes in directors' interest & trades for Epiminder Limited (EPI) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
| Name | Position |
|---|---|
| Mark McLellan | Chief Financial Officer,Joint Company Secretary |
| Belinda Ann Cleminson | Joint Company Secretary |
| Date | Event |
|---|---|
| 24 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.